Point Therapeutics to Host Third Quarter 2006 Results Conference Call/Audio Webcast

  
    
  
  
    
      Point Therapeutics, Inc. (NASDAQ: POTP) announced today that it will 
      release third quarter 2006 results on Thursday, November 9, 2006, after 
      the close of the U.S. financial markets. A conference call will follow 
      at 4:30 PM Eastern Time, to review the results and provide an update on 
      the Company's progress.
    
    
      Participants are invited to attend the call by visiting www.pther.com or 
      by dialing:
    
    
      800-591-6944 (International: 617-614-4910)
    
    
      Passcode: 66385651
    
    
      A re-broadcast of the conference call will be available until November 
      16, 2006 and accessible by dialing:
    
    
      888-286-8010 (International: 617-801-6888)
    
    
      Passcode: 78019990
    
    
      About Point Therapeutics, Inc.:
    
    
      Point is a Boston-based biopharmaceutical company developing a portfolio 
      of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 
      diabetes and as vaccine adjuvants. Point is currently studying its lead 
      product candidate, talabostat, in two Phase 3 trials in non-small cell 
      lung cancer. Point is also studying talabostat in several Phase 2 
      trials, including as a single-agent in metastatic melanoma, in 
      combination with cisplatin in metastatic melanoma, in combination with 
      rituximab in advanced chronic lymphocytic leukemia, and in combination 
      with gemcitabine in metastatic pancreatic cancer.
    
  
Point Therapeutics, Inc. (NASDAQ: POTP) announced today that it
will release third quarter 2006 results on Thursday, November 9, 2006,
after the close of the U.S. financial markets. A conference call will
follow at 4:30 PM Eastern Time, to review the results and provide an
update on the Company's progress.

   Participants are invited to attend the call by visiting
www.pther.com or by dialing:

   800-591-6944 (International: 617-614-4910)

   Passcode: 66385651

   A re-broadcast of the conference call will be available until
November 16, 2006 and accessible by dialing:

   888-286-8010 (International: 617-801-6888)

   Passcode: 78019990

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.